Gartner and Revvity beat third-quarter estimates and raise full-year outlooks

what happened

Gartner posted third-quarter revenue of $1.50 billion against $1.49 billion expected by analysts, while adjusted earnings per share came in at $3.59 versus an estimate of $2.84. Adjusted EPS rose 30% from a year earlier. The company raised its 2026 forecasts for revenue, adjusted EBITDA, adjusted EPS and free cash flow, and bought back 0.9 million shares for $138 million in the quarter. CEO Gene Hall said accelerating contract value growth helped the results.

Revvity reported revenue of $729 million, above the $698.15 million consensus and up 7% year on year. Adjusted EPS was $1.37 against $1.30 expected. For 2026 the company expects pro forma revenue of about $2.86 billion, organic growth of roughly 5% and pro forma adjusted EPS of $5.40 to $5.45. Life Sciences grew 11% and Diagnostics rose 4%.

why it matters

Both reports point to recovering corporate demand in data and life-science tools, and higher guidance typically supports share prices. Still, average analyst ratings on both stocks remain at hold, and Gartner's median price target sits below its recent trading level, so the market reaction may be mixed.

market impact

Gartner and Revvity shares: strong results and higher guidance support the stocks

• ▲Gartner shares pressure up — quarterly profit above estimates and a raised full-year outlook
• ▲Revvity shares pressure up — revenue and profit above consensus and a higher annual forecast

tags

instruments